<i id='3D3085EB6A'><strike id='3D3085EB6A'><tt id='3D3085EB6A'><pre id='3D3085EB6A'></pre></tt></strike></i> 
EQRx is done, sold for its cash.
The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.
advertisement
The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTED Log In
Medical records are filled with copy 
Protect nursing home residents from future pandemics 
Peter Hotez and the public health issue of online harassment 
Bubonic plague hit France in 1720. Officials dithered. Sound familiar? 
Cancer drug shortages should be causing more outrage 
Clinicians often fail to acknowledge the pain caused by long Covid 
Malaria cases in Florida and Texas: Here’s what you need to know 
First transplant of an entire human eye performed 
Guidelines to prevent youth baseball injuries need more muscle 
Beyond aggravation: Constipation is an American epidemic 
Sports medicine is finally prioritizing gender equality 
Pharma’s losing bet in New Jersey
Cancer drug shortages should be causing more outrage 
Medical school prerequisites are outdated 
ChatGPT in medicine: STAT answers readers' burning questions 
